Abstract

Senior Skilled Nursing Participants' Biocompatibility to Three Different Influenza Vaccines Against Homologous and Heterologous Strains

Author(s): Richard J. Webby

We looked at how well the MF59 adjuvant in the influenza vaccine protects older people living in institutions from drifting influenza viruses [1]. Hemagglutination inhibition (HI) assays were used to retest sera from a randomised research comparing MF59-adjuvanted (Sub/MF59), virosomal (SVV), and split vaccinations. The GMTs against homologous A/ H3N2 and B and both drifting A strains were considerably higher for Sub/MF59 than split, and corrected postvaccination HI antibody titres were significantly greater with Sub/MF59 than SVV for all strains. For all A influenza strains, Seroprotection rates and mean-fold titer increases were generally higher with Sub/MF59. [2] In comparison to traditional virosomal and split vaccinations, MF59-adjuvanted influenza vaccine generated higher and broader immune responses in older patients with chronic illnesses, especially for A/H1 and A/ H3 strains, potentially indicating that delivering therapeutic benefit during antigenic mismatch seasons.